11 stories mentioning SRRKUpdated 7d ago
Every FINWIRES story that references SRRK, newest first.
Recent broker actions mentioned in FINWIRES coverage. Compiled from wire headlines; not investment advice.
Scholar Rock (SRRK) shares were down about 5.2% in Tuesday trading after Barclays downgraded the stock to equalweight from overweight and raised its price target to $58 from $55.Intraday trading volume stood at nearly 3.5 million shares against a daily average of roughly 1.4 million.Price: $49.16, Change: $-2.69, Percent Change: -5.19%
Scholar Rock (SRRK) could face some friction during the early commercialization of Isembyld after the drugmaker clarified that the US Food and Drug Administration has required a post-marketing pregnancy safety study and requested 15-day reports for serious and non-serious fracture cases, Truist Securities said in a note Tuesday.The FDA recently approved Isembyld to treat spinal muscular atrophy in adults and children two years of age and older.The fracture rate observed in the Isembyld trial appears consistent with historical rates in patients with spinal muscular atrophy, while management reported no change in bone mineral density in the Phase 2 EMBRACE study, Truist said.The brokerage expects fracture reports to be reflected in periodic FDA Adverse Event Reporting System updates, as Scholar Rock does not expect to announce individual new fracture cases.Truist continues to see potential for Isembyld to reach peak sales of $2.3 billion.Truist maintained a buy rating with $76 price target.Price: $47.83, Change: $-4.02, Percent Change: -7.75%
Scholar Rock Holding (SRRK) has an average rating of buy and mean price target of $69.62, according to analysts polled by FactSet.
Scholar Rock Holding (SRRK) won early regulatory approval of Isembyld to treat spinal muscular atrophy, a "positive surprise" that lifts a key regulatory hurdle, UBS Securities said Sunday in a report.Isembyld was approved with a broad label for patients aged 2 years and older ahead of its Prescription Drug User Fee Act date on Sept. 30, and the commercial rollout is expected to be gradual, generating $5 million in revenue this year, in line with market expectations, the report said.UBS expects uptake to accelerate as reimbursement pathways become more streamlined, generating peak sales of $1.5 billion to $2 billion, "particularly given the substantial unmet need" in spinal muscular atrophy.While Isembyld's label notes an imbalance in fracture rates between the treatment group and placebo group in the late-stage study, the overall benefits outweigh the risks, the report said.UBS maintained its buy rating on Scholar Rock's stock and its $60 price target.Price: $53.61, Change: $-1.80, Percent Change: -3.25%
Scholar Rock Holding (SRRK) has an average rating of buy and mean price target of $65.60, according to analysts polled by FactSet.Price: $53.19, Change: $-2.22, Percent Change: -4.01%
The broad market exchange-traded fund SPDR S&P 500 ETF Trust (SPY) was down 0.6%, and the actively traded Invesco QQQ Trust (QQQ) was 1.5% lower in Monday's premarket activity as warnings from AI industry leaders weighed on technology shares.US stock futures were also lower, with S&P 500 Index futures down 0.6%, Dow Jones Industrial Average futures slipping 0.2%, and Nasdaq futures retreating 1.5% before the start of regular trading.In premarket activity, bitcoin was up by 0.8%. Among cryptocurrency ETFs, the cryptocurrency fund ProShares Bitcoin Strategy ETF (BITO) was 0.9% higher, Ether ETF (EETH) retreated 1.1%, and Bitcoin & Ether Market Cap Weight ETF (BETH) gained 0.7%.Power Play:TechnologyThe State Street Technology Select Sector SPDR ETF (XLK) retreated 2.5%, the iShares US Technology ETF (IYW) was flat, and the iShares Expanded Tech Sector ETF (IGM) was down 2%. Among semiconductor ETFs, the State Street SPDR S&P Semiconductor ETF (XSD) was inactive, while the iShares Semiconductor ETF (SOXX) fell by 5.6%.Elastic (ESTC) shares were up more than 7% in premarket activity after the company said Friday that it launched the serverless Elasticsearch Vector Database with optimized defaults to enable developers to create and ship vector search applications faster.Winners and Losers:Health CareThe State Street Health Care Select Sector SPDR ETF (XLV) advanced 1%, the Vanguard Health Care Index Fund (VHT) was up 0.4%, while the iShares US Healthcare ETF (IYH) was inactive. The iShares Biotechnology ETF (IBB) was down 0.2%.Scholar Rock (SRRK) stock was 6% higher after the company said Friday it received US Food and Drug Administration approval for Isembyld to treat spinal muscular atrophy in certain patients aged two years and above.FinancialThe State Street Financial Select Sector SPDR ETF (XLF) advanced 0.1%. Direxion Daily Financial Bull 3X Shares (FAS) was up 0.6%, while its bearish counterpart, Direxion Daily Financial Bear 3X Shares (FAZ), was flat.Baldwin Insurance Group (BWIN) shares traded up 6% after the company said it has entered into a definitive agreement through which an entity formed by Sequence Holdings and the Dell Family Office will acquire a majority interest in the company for about $7.70 billion in cash.IndustrialThe State Street Industrial Select Sector SPDR ETF (XLI) retreated 1.4%, while the Vanguard Industrials Index Fund (VIS) and the iShares US Industrials ETF (IYJ) were inactive.SpaceX (SPCX) shares were down more than 2% before the opening bell. The company's Chief Executive Elon Musk said Sunday on social media platform X that he is "highly confident" the company will launch Nvidia's (NVDA) Vera Rubin NLV72 artificial intelligence computers in space next year.EnergyThe iShares US Energy ETF (IYE) gained 0.9%, while the State Street Energy Select Sector SPDR ETF (XLE) was up by 1.5%.Occidental Petroleum (OXY) stock was up more than 2% before market open after Wells Fargo lifted the company's price target to $82 from $79.ConsumerThe State Street Consumer Staples Select Sector SPDR ETF (XLP) was up 1%, the Vanguard Consumer Staples Index Fund ETF Shares (VDC) was inactive, and the iShares US Consumer Staples ETF (IYK) was 0.3% higher. The State Street Consumer Discretionary Select Sector SPDR ETF (XLY) lost 0.5%. The VanEck Retail ETF (RTH) and the State Street SPDR S&P Retail ETF (XRT) were inactive.Kenvue (KVUE) and Kimberly-Clark (KMB) shares were up 1% after Reuters reported Kimberly-Clark is preparing potential asset sales to address EU antitrust concerns over its proposed acquisition of Kenvue.CommoditiesFront-month US West Texas Intermediate crude oil was up by 4.7% at $104.79 per barrel on the New York Mercantile Exchange. Natural gas was 2.3% higher at $2.90 per 1 million British Thermal Units. The United States Oil Fund (USO) rose 3.1%, while the United States Natural Gas Fund (UNG) advanced 1.5%.Gold futures for November were down by 1.9% at $4,324.40 an ounce on the Comex. Silver futures fell 2.5% to $63.57 an ounce. SPDR Gold Shares (GLD) decreased 1.8%, and the iShares Silver Trust (SLV) was 2.3% lower.
Scholar Rock's (SRRK) latest update further de-risks the global apitegromab regulatory path, given the potential approval in the US and clear view on the Japan registration path, offsetting a delay in Europe, Wedbush said Friday.Earlier, Scholar Rock confirmed removal of Novo Nordisk's (NVO) Catalent Indiana as a commercial fill-finish facility from its US biologics license application, and it expects an approval decision from the US Food and Drug Administration by Sept. 30 for apitegromab as a treatment for spinal muscular atrophy.In Europe, Scholar Rock said it withdrew its marketing authorization application following the Catalent inspection issue and plans to resubmit with the new facility. In Japan, no additional clinical studies are needed, allowing a new drug application filing by year-end.Wedbush reiterated its outperform rating on Scholar Rock's stock and raised its price target to $64 from $58.Price: $56.16, Change: $+0.91, Percent Change: +1.64%
Wedbush Adjusts Scholar Rock Price Target to $64 From $58, Maintains Outperform Rating
Scholar Rock (SRRK) reported a Q2 net loss Thursday of $0.84 per diluted share, compared with a loss of $0.98 a year earlier.Analysts polled by FactSet expected a loss of $0.84.As expected, the company reported no revenue for the quarter ended June 30.Cash, cash equivalents, and marketable securities as of June 30 totaled $492.1 million.Shares of the company were up over 6% in Thursday premarket activity.Price: $50.93, Change: $+3.06, Percent Change: +6.40%
Scholar Rock (SRRK) has an average rating of buy and mean price target of $57.73, according to analysts polled by FactSet.
David Hallal, Director, Chief Executive Officer, on April 16, 2026, sold 30,615 shares in Scholar Rock Holding (SRRK) for $1,517,723. Following the Form 4 filing with the SEC, Hallal has control over a total of 1,844,034 common shares of the company, with 1,639,034 shares held directly and 205,000 controlled indirectly.SEC Filing:https://www.sec.gov/Archives/edgar/data/1727196/000110465926045581/xslF345X05/tm2612274-1_4seq1.xml
